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AbstrACt
Introduction Many patients with psychosis experience 
everyday social situations as anxiety-provoking. The fears 
can arise, for example, from paranoia, hallucinations, social 
anxiety or negative-self beliefs. The fears lead patients to 
withdraw from activities, and this isolation leads to a cycle 
of worsening physical and mental health. Breaking this cycle 
requires highly active treatment directly in the troubling 
situations so that patients learn that they can safely and 
confidently enter them. However patients with psychosis 
seldom receive such life-changing interventions. To solve 
this problem we have developed an automated psychological 
treatment delivered in virtual reality (VR). It allows patients to 
experience computer simulations of the situations that they 
find anxiety-provoking. A virtual coach guides patients, using 
cognitive techniques, in how to overcome their fears. Patients 
are willing to enter VR simulations of anxiety-provoking 
situations because they know the simulations are not real, 
but the learning made transfers to the real world.
Methods and analysis 432 patients with psychosis and 
anxious avoidance of social situations will be recruited 
from National Health Service (NHS) secondary care 
services. In the gameChange trial, they will be randomised 
(1:1) to the six-session VR cognitive treatment added 
to treatment as usual or treatment as usual alone. 
Assessments will be conducted at 0, 6 (post-treatment) 
and 26 weeks by a researcher blind to allocation. The 
primary outcome is avoidance and distress in real-
life situations, using a behavioural assessment task, 
at 6 weeks. The secondary outcomes are psychiatric 
symptoms, activity levels and quality of life. All main 
analyses will be intention-to-treat. Moderation and 
mediation will be tested. An economic evaluation will be 
conducted.
Ethics and dissemination The trial has received ethical 
approval from the NHS South Central - Oxford B Research 
Ethics Committee (19/SC/0075). A key output will be 
a high-quality automated VR treatment for patients to 
overcome anxious avoidance of social situations.
trial registration number ISRCTN17308399.
bACkground
rationale
Too many patients with psychosis, despite 
standard treatment, become isolated and 
inactive, with negative effects on both mental 
and physical health. Approximately 80% of 
patients with schizophrenia experience an 
episode of depression.1 Physical activity levels 
in patients with schizophrenia are reduced 
on average by approximately two-thirds.2 
Over 90% of patients with schizophrenia are 
unemployed and spend ‘less time in func-
tional but also in social and leisure activities 
and more time resting and ‘doing nothing’ 
strengths and limitations of this study
 ► A multicentre randomised controlled trial of 432 pa-
tients with psychosis being seen in National Health 
Service mental health trusts, which will be the larg-
est trial of virtual reality (VR) used to treat a mental 
health condition.
 ► Automated delivery of the VR intervention meaning 
high treatment fidelity and a highly scalable treat-
ment that could greatly increase access to psycho-
logical therapy.
 ► Mediation built into the treatment design can test 
whether the treatment works as hypothesised.
 ► The control condition is treatment as usual meaning 
that it cannot be definitively established which VR 
treatment elements produce clinical change.
 ► It is impossible to blind patients to the treatment 
allocation, which could introduce bias into the treat-
ment effect estimation.
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compared with the general population’.3 Life expectancy 
is on average 14.5 years shorter,4 due to largely prevent-
able conditions such as high blood pressure, diabetes 
and heart disease. Partly this physical ill health reflects 
unhealthy lifestyles including inactivity.
Our view is that a substantial part of this inactivity 
arises from avoidance due to anxiety. In a clinical assess-
ment study of 1800 patients with non-affective psychosis 
attending National Health Service mental health services, 
two-thirds of the patients had levels of anxious avoidance 
equivalent to patients diagnosed with agoraphobia.5 The 
anxiety in patients with psychosis can arise from a number 
of sources: fears that others will harm them, voices telling 
them of danger, social anxiety fears of humiliation and 
rejection and negative beliefs about the self that cause a 
lack of confidence and a sense of vulnerability. But with-
drawal from activities because of anxiety need not be 
inevitable. Appropriate treatment, as seen in the anxiety 
disorders,6 can produce excellent outcomes. Such treat-
ment involves identifying fearful thoughts and the safe-
ty-seeking (or defence) behaviours that maintain those 
cognitions by preventing receipt and processing of discon-
firmatory evidence. The thoughts must then be tested in 
behavioural experiments in the troubling situations while 
the defence behaviours are dropped.7 However, there is 
a dearth of therapists to carry out this skilled work for 
patients with schizophrenia. It is well-recognised that 
there is considerable under-provision of psychological 
therapy for patients with schizophrenia.8 There is the 
additional problem that sometimes very fearful beliefs 
of patients with psychosis mean that they can be much 
less likely to engage in behavioural experiments in the 
real world before their fears have been lessened by other 
means. Our solution is the provision of automated psycho-
logical therapy using virtual reality (VR).
Virtual reality (interactive computer-generated envi-
ronments) has been used since the early 1990’s to treat 
anxiety.9 Meta-analyses indicate that VR treatments for 
anxiety disorders can produce large treatment effects10 
that generalise to the real world.11 Previous uses of VR 
for mental health problems have depended on a thera-
pist providing the psychological therapy.12 In a trial of 100 
patients with a fear of heights, we have shown that the 
provision of cognitive therapy can be automated using VR 
by the incorporation of a virtual coach.13 The treatment 
effect sizes in this trial were very large (effect size Cohen’s 
d=2.0; the number of patients needed to treat to at least 
halve fear of heights was 1.3), and better than expected 
from face-to-face therapy. Automated treatment has the 
potential to be scalable, removing a key cause of the 
highly limited access to psychological therapy for patients 
with psychosis.
VR may also be especially suited to the difficulties of 
patients with psychosis. Patients with strong fears are 
much more likely to test out their fear expectations in 
VR because they know it is a simulation but the learning 
that they make then transfers to the real world. VR treat-
ment can also include engaging tasks that make the 
treatment experience much more pleasurable. A graded 
approach can easily be applied in VR, allowing the indi-
vidual to repeatedly experience the situations they find 
difficult and make new learning. Our view is that VR 
treatments have the potential to be faster, more effica-
cious and appealing to patients than traditional face-to-
face approaches. We conducted a first test of VR to treat 
persecutory delusions in patients with psychosis.14 Just 30 
minutes in graded VR environments, with the psycholog-
ical advice provided by a therapist, led to a large reduc-
tion in distress in real-world situations (eg, going into a 
shop). VR has been shown to be safe to use with patients 
with psychosis.15 A recent randomised controlled trial 
of over 100 patients with psychosis showed that sixteen 
1 hour sessions with VR environments and a therapist 
who administered cognitive behavioural therapy tech-
niques led at follow-up to a moderate increase in time 
spent with other people as assessed by an experience 
sampling method.16 In the THerapeutic Realistic Immer-
sive Virtual Environments (THRIVE) trial our team is 
currently testing a four-session automated VR cognitive 
treatment for patients specifically with persecutory delu-
sions (ISRCTN12497310).17
In the gameChange project ( www. gameChangeVR. 
com), we have recently developed - using a socially-inclu-
sive design process - a new automated VR cognitive treat-
ment for patients for psychosis having difficulties being 
in everyday social situations due to anxiety. It is designed 
to be easy to use, engaging for patients and staff and 
delivered with the latest consumer equipment. Therefore 
this VR treatment has the potential to be widely imple-
mented in treatment services. Psychological treatment 
that involves direct coaching in the situations that trouble 
patients with psychosis is rarely available in mental health 
services. Therefore we set out to determine the in toto 
effects of adding the VR treatment to treatment as usual. 
This entails a test that randomises patients to receive the 
VR treatment in addition to usual care or to usual care. 
We aim to determine the clinical effects on real-world 
performance, activity levels, psychiatric symptoms and 
quality of life.
Aims and hypotheses
The primary research question we aim to test is: Does 
automated VR cognitive treatment added to treatment as 
usual, compared with treatment as usual alone, lead to 
a post-treatment reduction in real world avoidance and 
distress for patients with psychosis attending NHS mental 
health services?
Our primary hypothesis is that:
1. Compared with treatment as usual, VR cognitive 
therapy added to treatment as usual will reduce avoidance 
and distress of real world situations (post-treatment).
Our secondary hypotheses are:
1. Compared with treatment as usual, VR cognitive ther-
apy added to treatment as usual will reduce psychiatric 
symptoms (paranoia, anxious avoidance, depression, 
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Figure 1 Trial flow diagram. TAU, treatment as usual; VR, virtual reality.
suicidal ideation), increase activity and improve quality 
of life (post-treatment).
2. Treatment effects will be maintained at follow-up (6 
months).
3. The mediators of VR treatment will be safety beliefs, 
threat cognitions and defence behaviours.
4. Treatment effects will be moderated by the occurrence 
of negative auditory hallucinations in social situa-
tions, hopelessness, appearance concerns and threat 
cognitions.
We also include a health economic evaluation of the 
VR treatment. It will focus on determining the cost of the 
VR treatment using a microcosting approach, performing 
a within-trial cost-effectiveness analysis and extrapolating 
the within-trial results to a 10 years horizon using a 
state-transition model.
MEthods And AnAlysIs
trial design and flow chart
The design is a multicentre, parallel group randomised 
controlled trial with single blind assessment to test whether 
the automated VR cognitive treatment added to treat-
ment as usual, compared with treatment as usual alone, 
leads to a post-treatment reduction in real world distress 
and avoidance for patients with psychosis attending 
NHS mental health services. Treatment as usual will be 
measured but remain unchanged in both groups. Assess-
ments will be carried out at 0 (baseline), 6 (post-treat-
ment) and 26 (follow-up) weeks by a researcher blind to 
treatment allocation. A summary of the trial design can 
be seen in figure 1. The trial is prospectively registered 
with the ISRCTN registry: ISRCTN17308399. There is a 
Data Monitoring and Ethics Committee.
randomisation, blinding and code-breaking
Participants will be randomised once they have completed 
the baseline assessment. Participants will be allocated to 
one of the trial arms using a 1:1 allocation ratio. Rando-
misation will be carried out by a validated online system, 
Sortition, designed by the University of Oxford Primary 
Care Clinical Trials Unit. Randomisation using a permuted 
blocks algorithm, with randomly varying block size, will 
be stratified by site (Bristol/Manchester/Newcastle/
Nottingham/Oxford) and service type (in-patient/early 
intervention/community mental health team).
The research assessors will be blinded to group alloca-
tion, but the patients and staff member present will not 
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be (they cannot be blinded to whether psychological 
intervention is delivered or received). If an allocation 
is revealed between assessment sessions, this is logged 
by the trial coordinator and re-blinding will occur using 
another assessor.
Participants
The trial participants will be patients with psychosis and 
self-reported difficulties going outside among other 
people due to anxiety. The principal method of recruit-
ment will be via seeking referrals to the trial from the 
relevant clinical teams (adult community mental health 
teams; early intervention services, and inpatient units) in 
the participating mental health trusts. The trial centres 
will be Bristol, Manchester, Newcastle, Nottingham, 
Oxford, with recruitment from local NHS mental health 
trusts. With the approval of the clinical team, patients 
interested in taking part will then be approached by the 
research team, given information about the trial, and 
screening conducted. Our Lived Experience Advisory 
Panel (LEAP) have also emphasised the importance of 
patients of the participating trusts self-initiating referral 
to the trials, in order to minimise the chances that partic-
ular patients are overlooked by clinical teams or the clini-
cian was not present at a referral meeting. Hence we will 
also advertise the study and patients within participating 
trusts will be able to self-refer for a screening to take part 
in the study. However, in all instances we will also seek to 
confirm that a member of the clinical team gives approval 
for a patient to enter the trial. Informed consent will be 
obtained from all patients before participation.
Inclusion criteria
 ► Adults aged 16 years or older;
 ► Attending an NHS mental health trust for the treat-
ment of psychosis;
 ► Clinical diagnosis of schizophrenia spectrum 
psychosis (F20 to F29) or an affective diagnosis with 
psychotic symptoms (F31.2, 31.5, 32.3, 33.3) (Interna-
tional Statistical Classification of Diseases and Related 
HealthProblems: Tenth Revision);18
 ► Having self-reported difficulties going outside their 
home primarily due to anxiety that they would like 
treated;
 ► And participant is willing and able to give informed 
consent for participation in the trial.
Exclusion criteria
 ► Unable to attempt an Oxford-Behavioural Assess-
ment Task (O-BAT) (the primary outcome measure) 
at baseline (eg, due to being unpermitted to leave a 
psychiatric ward);
 ► Photosensitive epilepsy;
 ► Significant visual, auditory or balance impairment;
 ► Current receipt of another intensive psychological 
therapy (or about to start it within the 6 week trial 
therapy window);
 ► Insufficient comprehension of English;
 ► In forensic settings or psychiatric intensive care unit;
 ► Organic syndrome;
 ► Primary diagnosis of alcohol or substance disorder or 
personality disorder;
 ► Significant learning disability;
 ► Or current active suicidal plans.
Assessments
Basic demographic and clinical data will be collected (eg, 
age, gender, ethnicity, clinical diagnosis, medication use). 
The primary outcome, avoidance and distress of everyday 
situations as measured by the O-BAT (adapted from 14), 
will be measured at baseline, 6 weeks and 26 weeks. The 
O-BAT comprises a personalised hierarchy of five real 
world tasks that the patient finds difficult due to anxiety. 
The person then tries to carry out the hierarchy, rating 
anxiety at each step achieved, and stopping when they 
decide the anxiety is too great. This therefore produces 
an avoidance score (0 to 5, with higher scores indicating 
lower avoidance) and a distress score (0 to 10, with higher 
scores indicating greater distress) for each level. All asses-
sors receive training in administering the O-BAT and the 
manual. The initial O-BAT for each participant is reviewed 
by a clinician. A detailed assessment of social avoidance 
is first carried out using both a semi-structured interview 
and a self-report measure of social avoidance, the self-re-
port O-BAT.19 This identifies the everyday situations and 
tasks that are anxiety-provoking for the participant, and 
provides a predicted level of distress for each. Based on 
this, the five-step personalised hierarchy is developed. A 
hierarchy can be constructed within one or a number of 
feared situations (eg, standing on the front door step for 
3 min, standing outside the front gate for 3 min, walking 
down the local street, walking to the local shop, buying 
something in the shop). The hierarchy is set up so that it is 
likely that the patient may only complete a small number of 
steps at baseline. Secondary outcomes will also be assessed 
at all three time-points. Anxious avoidance (AMI-A20 
and self-report version of the O-BAT19), suicidal ideation 
(Columbia Suicide Severity Rating Scale),21 overall para-
noia (R-GPTS),22 23 paranoia worries (Paranoia Worries 
Questionnaire)24 and levels of depression (PHQ-9)25 will 
be assessed. Activity levels will be assessed using actigraphy 
(over 7 days), complemented with a time-budget assessing 
meaningful activity.26 The EQ-5D-5L27 and ReQol28 will 
assess quality of life. Additionally, quality of life will be 
assessed using the Questionnaire about the Process of 
Recovery (QPR).29 For mediation, we will assess, at all time-
points, threat cognitions and use of defence behaviours 
(CDBQ)30 and strength of safety, vulnerability and threat 
anticipation beliefs.31 Moderators will be assessed at base-
line only by a brief assessment of negative hallucinations 
when outside,32 the Beck Hopelessness Scale,33 the Body-Es-
teem Scale for Adolescents and Adults34 and the Cognition 
and Defence Behaviours Questionnaire.30 We will record 
service use, and other relevant health economic data, 
using the Client Service Receipt Inventory.35 A summary of 
the measures is provided in table 1.
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Table 1 Summary of objectives and assessment measures
Objectives Outcome measures
Primary Test whether the virtual reality treatment leads to 
reduction in avoidance and distress in everyday 
situations.
Oxford - behavioural assessment task (O-BAT).
Secondary 1.Test clinical improvements by treatment type in 
activity levels, psychiatric symptoms, quality of life.
Activity levels: Actigraphy, time-budget measure.
Psychiatric symptoms: Agoraphobia mobility 
inventory-avoidance, self-report O-BAT, Revised Green 
et al Paranoid Thoughts Scale, Paranoia Worries 
Questionnaire, PHQ-9, Columbia-Suicide Severity 
Rating Scale.
Quality of life: EQ-5D-5L, ReQol, Questionnaire on the 
Progress of Recovery.
2.Determine the cost-effectiveness of the virtual reality 
treatment.
Client Service Receipt Inventory.
3.Test mediation of treatment effects by changes in 
safety beliefs, threat cognitions, and defence (safety-
seeking) behaviours.
Cognition and Defence Behaviours Questionnaire and 
strength of safety beliefs, vulnerability belief and threat 
anticipation.
  4.Test moderation of treatment effects (negative 
auditory hallucinations when outside, hopelessness, 
appearance concerns and threat cognitions).
Hallucinations scale; Beck Hopelessness Scale; Body-
Esteem Scale for Adolescents and Adults; Cognition 
and Defence Behaviours Questionnaire.
  5. Assess patient satisfaction with the VR therapy. Modified version of the Client Satisfaction 
Questionnaire.
VR, virtual reality.
the Vr psychological treatment
The gameChange VR treatment is a virtual-reality appli-
cation recommended for adults (16+) who have anxi-
eties when outside in everyday social situations. This 
software is intended to reduce anxieties around other 
people and therefore to help participants feel safer 
and more comfortable around people. The aim for the 
outcome is that patients feel more able to go outside into 
everyday situations. The treatment was programmed by 
the University of Oxford spin-out company Oxford VR 
( www. oxfordvr. org). The treatment is a CE marked Class 
I Active Medical Device- Z301 (Standalone Software), in 
conformity with the essential requirements and provi-
sions of the EC Directive 93/42/EEC (Medical Devices).
A mental health professional, most likely a peer support 
worker or psychology assistant, will be in the room when 
the treatment is given. This person will help the patient 
put on the VR headset and start the programme. The 
staff member will also encourage the person to apply the 
learning from VR into the real world through the setting 
up of homework tasks to be carried out between sessions. 
The applications will run through the Steam software 
application on a laptop computer connected to a head-
mounted display and accessories. All hardware is already 
commercially available and has not been modified for 
the trial. Satisfaction will be assessed after completion of 
the last treatment session using a modified version of the 
Client Satisfaction Questionnaire.36
The VR Cognitive Therapy (VRCT/gameChange treat-
ment) aims for patients to test their fear expectations 
around other people in order to relearn safety. The 
treatment is not designed as exposure therapy (partici-
pants are not asked to remain in situations until anxiety 
reduces) but as repeated behavioural experiment tests 
(to learn that they are safer than they had thought). The 
treatment is designed to be delivered in approximately 
six sessions of 30 minutes. Three sessions will be consid-
ered the minimum (adherent) dose of therapy. However 
participants can proceed at their own pace, meaning 
that a fewer or greater number of sessions is allowed. 
The participant typically stands, and is able to walk a few 
paces in the scenarios. A virtual coach guides the person 
through the treatment, including encouraging the drop-
ping of defence behaviours, and elicits feedback to tailor 
the progression of the treatment. When first entering 
VR, the patient goes into the coach’s virtual office and is 
guided in how to use VR (ie, the basic functions). At the 
beginning of the first session, the virtual coach explains 
the rationale behind the treatment, and the participant 
selects which one of six virtual reality situations that they 
would like to begin in. The six virtual reality scenarios 
are a: café, general practitioner waiting room, pub, bus, 
street scene and shop. Each scenario has five levels of 
difficulty (eg, the number and proximity of people in the 
social situation increases) and participants work their way 
through each level of difficulty. There are (therapeutic) 
game type tasks within a number of the levels (that are 
designed to help the person drop defence behaviours 
and make new learning). The participant can choose a 
different scenario in each session or repeat a previous 
situation (and level). Throughout the sessions, partici-
pants’ responses to questions from the virtual coach are 
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Figure 2 The structure of the virtual reality treatment.
given by means of gripping a virtual globe. Belief ratings 
are repeated within VR at the beginning and end of each 
treatment session. Figure 2 provides a summary of the 
treatment design. A video about the gameChange treat-
ment can be viewed here: https://www. youtube. com/ 
watch? v= D31wodNAMZA.
Control condition
Participants who are allocated to the control arm will 
continue to receive their usual care. No additional inter-
ventions will be offered by the research team. Treatment 
as usual for the participants within this trial will typically 
consist of long-term prescription of psychiatric medica-
tions, and meetings with a mental health practitioner. 
Treatment as usual will vary across individuals and mental 
health trusts. We will collect detailed data on treatment 
as usual (which will also inform the health economic 
evaluation).
Adverse events
A trial standard operational procedure has been written 
for adverse events. We will record the occurrence of any 
serious adverse events reported to us and also check 
each patient’s medical notes at the end of their partic-
ipation in the trial. An adverse event is defined by the 
ISO14155:2011 guidelines for medical device trials as 
serious if it: (a) results in death or, (b) is a life-threat-
ening illness or injury or, (c) requires hospitalisation or 
prolongation of existing hospitalisation or, (d) results 
in persistent or significant disability or incapacity or, (e) 
medical or surgical intervention is required to prevent 
any of the above, (f) leads to foetal distress, foetal death 
or consists of a congenital anomaly or birth defect or 
(g) is otherwise considered medically significant by the 
investigator.
Life threatening in the definition of a serious adverse 
event refers to an event in which the subject was at risk of 
death at the time of the event; it does not refer to an event 
that hypothetically might have caused death if it were 
more severe. A planned hospitalisation for a pre-existing 
condition, without a serious deterioration in health, is 
not considered to be a serious adverse event. The sorts 
of serious adverse events that can typically happen to 
this participant group include: deaths, suicide attempts, 
serious violent incidents and admissions to hospital.
We will also record any adverse device effects from the 
VR treatment, which includes adverse events resulting 
from insufficient or inadequate instructions for use, 
deployment, installation or operation, or any malfunction 
of the software. It also includes any event resulting from 
user error or intentional misuse.
Analysis
A full statistical analysis plan will be drafted prior to 
recruitment beginning and approved before any anal-
ysis. We will report data in line with the Consolidated 
Standards of Reporting Trials 2010 Statement37 showing 
attrition rates and loss to follow-up. The primary analyses 
will be carried out using the intention-to-treat principle. 
That is, after randomisation, participants will be analysed 
according to their allocated intervention arm irrespec-
tive of what intervention they actually receive, and with 
data available from all participants included in the anal-
ysis including those who do not complete therapy. The 
outcome analyses will be conducted by statisticians in the 
University of Oxford Primary Care Clinical Trials Unit.
We will test the primary hypothesis for between-group 
difference in the primary outcome (O-BAT at 6 weeks) 
using a linear mixed effects model which models the 
response at 6 weeks and 26 weeks, with baseline outcome 
measure, stratification variables and treatment assign-
ment as fixed effects, with a patient specific random 
intercept. An interaction between time and randomised 
group will be fitted as a fixed effect to allow estimation 
of treatment effect at all time points. The linear mixed 
effects model will account for missing data assuming data 
are missing-at-random. Standard residual diagnostics 
will be assessed for the appropriateness of the model. P 
value <0.05 will be used as the level of statistical signifi-
cance. Similar mixed effect models will be used to analyse 
secondary outcomes. We will recruit around 432 partic-
ipants into this trial, with 216 in each arm. This sample 
size takes into consideration a maximum attrition rate of 
20%, and provide 90% power to detect a difference of 
around 8 (SD=23) in O-BAT anxiety score (using the 0 to 
100 scaling from Freeman et al, 201614), from randomisa-
tion to 6 weeks (ie, standardised effect size of 0.35) at 5% 
level of significance (two-sided).
The mediation analysis will investigate putative medi-
ational factors using modern causal inference methods. 
This involves using parametric regression models to test 
for mediation of VRCT on outcome through the puta-
tive mediators. Analyses will adjust for baseline measures 
of the mediator, outcomes and possible measured 
confounders. We will include repeated measurement of 
mediators and outcomes to account for classical measure-
ment error and baseline confounding. The identified 
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moderator variables (negative auditory hallucinations, 
hopelessness, appearance concerns and social phobia) 
will be considered for moderation of the intervention 
effect on the primary outcome.
A microcosting approach will be used to inform the cost 
per patient of the VR treatment. The within-trial health 
economic analysis will describe and compare the costs 
and outcomes of the two trial arms. Incremental cost per 
activity gained (primary outcome) will be estimated and 
the costs and remaining outcomes (utilities, psychiatric 
symptoms and well-being) assessed separately. This will be 
informed by a health economics statistical plan written 
prior to the economic analysis. The health economics 
will use an NHS and social care services perspective with 
resource utilisation valued using national cost data sets 
and EQ-5D-5L data converted into utilities using the UK 
tariffs. A broader perspective including lost earnings, 
patient out-of-pocket costs and criminal justice costs 
will also be considered. A state-transition model will be 
developed to extrapolate the within-trial analysis and esti-
mate the incremental costs per quality-adjusted life years 
(QALYs) gained from using the VR treatment, supported 
by the trial data, literature reviews and discussions with 
clinical experts. Uncertainty around the incremental 
cost-effectiveness ratio will be reported using the cost-ef-
fectiveness plane and the cost-effectiveness acceptability 
curve. The maximum reimbursable price of the VR treat-
ment conditional on the willingness to pay per QALY will 
be determined. We will then estimate the affordability to 
the NHS of a decision to implement the VR treatment. 
This will take the form of budget impact analysis using a 
time horizon of 3 years to be consistent with National Insti-
tute for Health and Care Excellence (NICE), informed by 
the results of the trial health economics analysis.
Patient and public involvement
The project has had extensive patient and public 
involvement (PPI). Principally this has occurred via The 
McPin Foundation, a charity that exists to ‘transform 
mental health research by putting the lived experience 
of people affected by mental health problems at the 
heart of research methods and the research agenda’. 
A grant-holder is from The McPin Foundation. Three 
other people with lived experience commented on the 
grant application and a focus group of people with lived 
experience was convened so that they could try VR and 
comment on the application.
Following the award of the grant there has been consid-
erable PPI. A LEAP has been formed to advise and shape 
the development of the treatment, the trial protocol and 
implementation into services. The LEAP comprises 10 
individuals with lived experience of psychosis drawn from 
each of the study sites (Bristol, Manchester, Newcastle, 
Nottingham, Oxford). For the protocol they have 
advised on: the choice of outcome measures, recruit-
ment methods, the format of recruitment materials and 
the content and wording of study materials. The LEAP 
have also reviewed and commented on the trial protocol 
document. In addition to the LEAP, we have also worked 
with people with lived experience from each of the trial 
sites to develop the VR treatment. A number of work-
shops were held. Through these workshops, people have 
contributed to the selection of the VR scenarios, the ther-
apeutic tasks within the scenarios and style of VR coach. 
These workshops entailed people with lived experience 
sharing their ideas, reviewing design concepts, and testing 
these out within VR. In addition to these workshops, there 
has been weekly input from a smaller group of individuals 
with lived experience to gain prompt feedback on details 
of design. There has been detailed user testing of the VR 
treatment during software development.
PPI will continue throughout the trial. First, LEAP meet-
ings will occur over the course of the trial. The LEAP will 
advise on any difficulties that occur in the trial. The LEAP 
will also contribute to the dissemination strategy. Second, 
there will be a qualitative evaluation of the VR treatment, 
with the interviews carried out by researchers with lived 
experience. This work will be run by The McPin Foun-
dation. Third, a McPin staff member sits on fortnightly 
gameChange review meetings and on the Research 
Steering Committee comprised of senior team members.
Ethics and dissemination
The trial has received Health Research Authority and 
Health and Care Research Wales approval (IRAS 256895, 
The gameChange trial). The trial received ethical approval 
from the NHS South Central - Oxford B Research Ethics 
Committee (19/SC/0075). The results of the trial will 
be published in a peer-reviewed journal and made open 
access. An anonymised version of the main outcome data 
will be available from the trial team on reasonable request 
after publication of the main results paper.
trial status
The trial is due to start patient recruitment in July 2019. 
Recruitment will be for a year until July 2020, with final 
outcome data collected by January 2021. A trial paper 
with the outcome results should be submitted for publica-
tion around April 2021.
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